Phase I result of ICP-192 (gunagratinib), a highly selective irreversible FGFR inhibitor, in patients with advanced solid tumors harboring FGFR pathway alterations.
Ye Guo(Army Medical University), Jin Li(Shanghai Cancer Institute), Xu Zhu(Children's Hospital of Chongqing Medical University), Jieer Ying(Chinese Academy of Medical Sciences & Peking Union Medical College), Renbin Zhao(Kunming University of Science and Technology), Chunwang Yuan(Capital Medical University), Bin Zhang(Northwestern University), Guodong Luan(Qingdao Institute of Bioenergy and Bioprocess Technology)
Cited by 10
Related Papers
Hepatogastroenterology
|Hepatogastroenterology|2012|1.3k
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial
|The Lancet Oncology|2023|663
Donafenib Versus Sorafenib in First-Line Treatment of Unresectable or Metastatic Hepatocellular Carcinoma: A Randomized, Open-Label, Parallel-Controlled Phase II-III Trial
|Journal of Clinical Oncology|2021|417